297 related articles for article (PubMed ID: 18466880)
1. Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative.
Carter CS; Barch DM; Buchanan RW; Bullmore E; Krystal JH; Cohen J; Geyer M; Green M; Nuechterlein KH; Robbins T; Silverstein S; Smith EE; Strauss M; Wykes T; Heinssen R
Biol Psychiatry; 2008 Jul; 64(1):4-10. PubMed ID: 18466880
[TBL] [Abstract][Full Text] [Related]
2. Cognitive neuroscience and schizophrenia: translational research in need of a translator.
Cohen JD; Insel TR
Biol Psychiatry; 2008 Jul; 64(1):2-3. PubMed ID: 18549873
[No Abstract] [Full Text] [Related]
3. The cognitive neuroscience of working memory: relevance to CNTRICS and schizophrenia.
Barch DM; Smith E
Biol Psychiatry; 2008 Jul; 64(1):11-7. PubMed ID: 18400207
[TBL] [Abstract][Full Text] [Related]
4. Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative.
Barch DM; Carter CS;
Schizophr Bull; 2008 Jul; 34(4):613-8. PubMed ID: 18499705
[TBL] [Abstract][Full Text] [Related]
5. Executive functioning component mechanisms and schizophrenia.
Kerns JG; Nuechterlein KH; Braver TS; Barch DM
Biol Psychiatry; 2008 Jul; 64(1):26-33. PubMed ID: 18549874
[TBL] [Abstract][Full Text] [Related]
6. Visual perception and its impairment in schizophrenia.
Butler PD; Silverstein SM; Dakin SC
Biol Psychiatry; 2008 Jul; 64(1):40-7. PubMed ID: 18549875
[TBL] [Abstract][Full Text] [Related]
7. The MATRICS consensus cognitive battery: what we know 6 years later.
Green MF; Harris JG; Nuechterlein KH
Am J Psychiatry; 2014 Nov; 171(11):1151-4. PubMed ID: 25756630
[No Abstract] [Full Text] [Related]
8. Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative.
Carter CS; Barch DM
Schizophr Bull; 2007 Sep; 33(5):1131-7. PubMed ID: 17630405
[TBL] [Abstract][Full Text] [Related]
9. The construct of attention in schizophrenia.
Luck SJ; Gold JM
Biol Psychiatry; 2008 Jul; 64(1):34-9. PubMed ID: 18374901
[TBL] [Abstract][Full Text] [Related]
10. The social-emotional processing stream: five core constructs and their translational potential for schizophrenia and beyond.
Ochsner KN
Biol Psychiatry; 2008 Jul; 64(1):48-61. PubMed ID: 18549876
[TBL] [Abstract][Full Text] [Related]
11. Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders.
Carter CS; Barch DM; Bullmore E; Breiling J; Buchanan RW; Butler P; Cohen JD; Geyer M; Gollub R; Green MF; Jaeger J; Krystal JH; Moore H; Nuechterlein K; Robbins T; Silverstein S; Smith EE; Strauss M; Wykes T
Biol Psychiatry; 2011 Jul; 70(1):7-12. PubMed ID: 21529781
[TBL] [Abstract][Full Text] [Related]
12. The cognitive neuroscience of memory function and dysfunction in schizophrenia.
Ranganath C; Minzenberg MJ; Ragland JD
Biol Psychiatry; 2008 Jul; 64(1):18-25. PubMed ID: 18495087
[TBL] [Abstract][Full Text] [Related]
13. New paradigms for treatment development.
Stover EL; Brady L; Marder SR
Schizophr Bull; 2007 Sep; 33(5):1093-9. PubMed ID: 17673495
[TBL] [Abstract][Full Text] [Related]
14. Imaging biomarkers for treatment development for impaired cognition: report of the sixth CNTRICS meeting: Biomarkers recommended for further development.
Carter CS; Barch DM;
Schizophr Bull; 2012 Jan; 38(1):26-33. PubMed ID: 21914642
[TBL] [Abstract][Full Text] [Related]
15. Wayne Fenton's impact on industry.
Breier A; Alphs L; Binneman B
Schizophr Bull; 2007 Sep; 33(5):1154-5. PubMed ID: 17562696
[No Abstract] [Full Text] [Related]
16. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
[TBL] [Abstract][Full Text] [Related]
17. Drug initiatives to improve cognitive function.
Marder SR
J Clin Psychiatry; 2006; 67 Suppl 9():31-5; discussion 36-42. PubMed ID: 16965187
[TBL] [Abstract][Full Text] [Related]
18. Stimulating the development of drug treatments to improve cognition in schizophrenia.
Green MF
Annu Rev Clin Psychol; 2007; 3():159-80. PubMed ID: 17716052
[TBL] [Abstract][Full Text] [Related]
19. Food and Drug Administration commentary on methodological issues in negative symptom trials.
Laughren T; Levin R
Schizophr Bull; 2011 Mar; 37(2):255-6. PubMed ID: 21245124
[No Abstract] [Full Text] [Related]
20. The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia.
Marder SR
Dialogues Clin Neurosci; 2006; 8(1):109-13. PubMed ID: 16640121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
